Evidence map›Paper›PMID 31382411›Full record

ArticleCancers2019

DNA-Methylation-Caused Downregulation of

Asfar S Azmi, Yiwei Li, Amro Aboukameel, Irfana Muqbil, Philip A Philip, Ramzi M Mohammad

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Deregulation of All-International journal of molecular sciences · 2023
    Review
  5. Emerging Role of MicroRNA-30c in Neurological Disorders.International journal of molecular sciences · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Asfar S AzmiDepartment of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Yiwei LiDepartment of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Amro AboukameelDepartment of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Irfana MuqbilDepartment of Chemistry, University of Detroit Mercy, Detroit, MI 48221, USA.
Philip A PhilipDepartment of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Ramzi M MohammadDepartment of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA. mohammad@karmanos.org.ORCID 0000-0001-8332-5246
Wayne State University · USUniversity of Detroit Mercy · US

Funding

Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic CancerR37CA215427 · NCI · WAYNE STATE UNIVERSITY · PI AZMI, ASFAR S · 2018 to 2024
$2.4M
NCI NIH HHS R37 CA215427NCI NIH HHS R37 CA215427 02
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, with high mortality in the United States. One of the important signal transduction proteins involved in the regulation of pancreatic cancer's aggressive progression is the nuclear export protein (XPO1). High expression of XPO1 has been found in pancreatic, lung, breast and other cancers and lymphomas with a poor prognosis of patients with tumors and high proliferative activity of cancer cells. Because XPO1 exports multiple tumor suppressor proteins simultaneously from the nucleus, the inhibition of XPO1 may retain multiple tumor suppressors in the nucleus, resulting in the suppression of cell proliferation and the induction of apoptosis in tumors. In this study, we found that the high expression of XPO1 in pancreatic cancer cells could be, in part, due to the methylation of the

Indexed as

methylationmiR-30pancreatic cancerproliferationXPO1

Identifiers

PMID31382411
PMCPMC6721494
OpenAlexW2966360581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.